{"protocolSection":{"identificationModule":{"nctId":"NCT00372775","orgStudyIdInfo":{"id":"A6181092"},"organization":{"fullName":"Pfizer","class":"INDUSTRY"},"briefTitle":"Study Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain Metastases","officialTitle":"A Phase 2 Efficacy And Safety Study Of SU011248 In Patients With Non-Small Cell Lung Cancer And Brain Metastases"},"statusModule":{"statusVerifiedDate":"2011-01","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2007-03"},"primaryCompletionDateStruct":{"date":"2009-12","type":"ACTUAL"},"completionDateStruct":{"date":"2009-12","type":"ACTUAL"},"studyFirstSubmitDate":"2006-09-05","studyFirstSubmitQcDate":"2006-09-05","studyFirstPostDateStruct":{"date":"2006-09-07","type":"ESTIMATED"},"resultsFirstSubmitDate":"2010-12-08","resultsFirstSubmitQcDate":"2011-01-27","resultsFirstPostDateStruct":{"date":"2011-02-24","type":"ESTIMATED"},"lastUpdateSubmitDate":"2011-01-27","lastUpdatePostDateStruct":{"date":"2011-02-24","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"oldNameTitle":"Director, Clinical Trial Disclosure Group","oldOrganization":"Pfizer Inc"},"leadSponsor":{"name":"Pfizer","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"This study will evaluate the safety, tolerability and efficacy of SU011248 in patients with non-small cell lung cancer with brain metastases."},"conditionsModule":{"conditions":["Non-Small Cell Lung Cancer"],"keywords":["brain metastases","Sunitinib","Phase 2"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":66,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Sunitinib","type":"EXPERIMENTAL","interventionNames":["Drug: Sunitinib"]}],"interventions":[{"type":"DRUG","name":"Sunitinib","description":"Sunitinib 37.5 mg daily by oral capsule in a continuous regimen until progression or unacceptable toxicity","armGroupLabels":["Sunitinib"],"otherNames":["Sutent"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Progression-Free Survival (PFS)","description":"Time in weeks from start of study treatment to first documentation of objective tumor progression or death due to any cause. Since day of first dose of medication and day criteria for progression were met, were each counted as a full day, 1 day was added to each calculation. PFS calculated as (first event date minus date of first dose of study medication plus 1) divided by 7.02. Used 7.02 days because it equals(=) 365 days per year divided by 52 weeks per year. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \\[PD\\]).","timeFrame":"Baseline, Day 1 of Week 5, 9, 17, 25, 33, and 41 to tumor progression or death (up to 1 year)"}],"secondaryOutcomes":[{"measure":"Time to Tumor Progression (TTP)","description":"Time from start of study treatment to first documentation of objective tumor progression. Tumor progression defined as greater than or equal to 20 percent (≥20%) increase in sum of longest dimensions of target lesions using as reference smallest sum of longest dimensions recorded since treatment started, or unequivocal progression of existing non-target lesions, or appearance of ≥1 new lesion, according to Response Evaluation Criteria in Solid Tumors (RECIST). TTP = (first event date minus date of first dose of study medication plus 1) divided by 7.02.","timeFrame":"Baseline, Day 1 of Week 5, 9, 17, 25, 33, and 41 to tumor progression (up to 1 year)"},{"measure":"Time to Neurological Progression (TNP)","description":"Time in weeks between first date criteria for focal neurological deficit were met and date of first dose of medication. Criteria for focal neurological deficit included speech or language difficulties, vision changes, loss of coordination or fine motor control, and seizures. Since day of first dose of medication and day criteria for focal neurological deficit were met were each counted as a full day, 1 day was added to each calculation. TNP was calculated as (first event date minus the date of first dose of study medication plus 1) divided by 7.02.","timeFrame":"Baseline, Day 28 to focal neurological deficit (up to 1 year)"},{"measure":"Number of Participants With Objective Disease Response","description":"Objective disease response defined as participants with confirmed complete response (CR) or partial response (PR), according to Response Evaluation Criteria in Solid Tumors (RECIST). CR defined as disappearance of all target lesions. PR defined as ≥30% decrease in sum of longest dimensions of target lesions taking as a reference the baseline sum longest dimensions.","timeFrame":"Baseline and Day 1 of Week 5, 9, 17, 25, 33, 41, and 49"},{"measure":"Time to Objective Intracranial Progression","description":"Time in weeks from start of study treatment to first documentation of objective intracranial tumor progression. Intracranial tumor progression defined as ≥25% increase from smallest size in sum of products of all enhancing tumors or appearance of any new tumor, according to World Health Organization (WHO) criteria. Since day of first dose of medication and day criteria for progression were met, were each counted as a full day, 1 day added to each calculation. Time to Objective Intracranial Progression = (first event date minus the date of first dose of study medication plus 1) divided by 7.02.","timeFrame":"Baseline, Day 1 of Week 5, 9, 17, 25, 33, and 41 to intracranial tumor progression (up to 1 year)"},{"measure":"Number of Participants With Intracranial Objective Disease Response","description":"Intracranial objective disease response defined as participants with confirmed CR or PR, according to WHO criteria. CR defined as disappearance of all enhancing tumor. PR defined as a ≥50% reduction from baseline in sum of the products of all enhancing tumors.","timeFrame":"Baseline and Day 1 of Week 5, 9, 17, 25, 33, 41, and 49"},{"measure":"Duration of Response (DR)","description":"DR defined as difference in weeks between first date criteria for progression occurred, or participant died due to any cause and first date that criteria for a PR or CR were met and subsequently confirmed ≥4 weeks later. Since day criteria for PR or CR were met and first day criteria for progression occurred (or participant died) were each counted as a full day, 1 day was added to each calculation. DR (in weeks) calculated as (first date of PD or death minus first date of CR or PR that was subsequently confirmed plus 1) divided by 7.02.","timeFrame":"Day 7 of Week 4 and every 4 weeks up to 1 year"},{"measure":"Overall Survival (OS)","description":"OS calculated as: (date of death minus date of first dose plus 1)divided by 30.4.","timeFrame":"Baseline until death (up to 1 year)"},{"measure":"Percentage of Participants Surviving at 1 Year","description":"Percentage of those surviving at end of 1 year from the first dose of study treatment.","timeFrame":"Year 1"},{"measure":"Number of Deaths Due to Intracranial Versus Systemic Progression","description":"Number of deaths determined to be intracranial versus systemic progression, according to investigators'assessment.","timeFrame":"Baseline until death (up to 1 year)"},{"measure":"Change From Baseline in Functional Assessment of Cancer Therapy/National Comprehensive Cancer Network (FACT/NCCN) Lung Symptom Index (FLSI) Score","description":"Change from baseline in FLSI Score was calculated Day 1 of Cycle 2 to 13. Each cycle = 28 days. Scores ranged from 0 to 24. Higher scores indicated better outcomes.","timeFrame":"Baseline, Day 1 of Week 5 and every 4 weeks to end of treatment (up to 1 year)"},{"measure":"Change From Baseline in FACT/NCCN Brain Symptom Index (FBrSI) Score","description":"Change from baseline in FBrSI Score was calculated Day 1 of Cycle 2 to 13. Each cycle = 28 days. Scores ranged from 0 to 60. Higher scores indicated better outcomes.","timeFrame":"Baseline, Day 1 of Week 5 and every 4 weeks to end of treatment (up to 1 year)"},{"measure":"Trough Plasma Concentrations (Ctrough) of Sunitinib","description":"A single blood sample (4 milliliters \\[mL\\]) collected pre-dose on Day 1 of Cycles 2, 3, and 4 to determine Ctrough of Sunitinib and its metabolite SU12662. Each cycle = 28 days. Ctrough defined as plasma concentration prior to study drug administration. Trough plasma concentrations were dose-corrected.","timeFrame":"Day 1 of Week 5, 9, and 13"},{"measure":"Ctrough of Sunitinib Metabolite (SU012662)","description":"A single blood sample (4 mL) collected pre-dose on Day 1 of Cycles 2, 3, and 4 to determine Ctrough of Sunitinib and its metabolite SU12662. Each cycle = 28 days. Ctrough defined as plasma concentration prior to study drug administration. Trough plasma concentrations were dose-corrected.","timeFrame":"Day 1 of Week 5, 9, and 13"},{"measure":"Correlation of Polymorphisms in c-Kit, Flt-3 and c-Fms With Blood Counts","description":"A blood sample (6mL) collected before treatment with Sunitinib and used to isolate deoxyribonucleic acid (DNA). These samples were not anonymized.","timeFrame":"Day 1 prior to dosing"},{"measure":"Percentage of Participants by Ribonucleic Acid (RNA) Expression Profile","description":"Tumor samples were not anonymized. RNA expression profile was to include colony-stimulating factor 1 receptor (CSF-1R), platelet-derived growth factor receptor alpha and beta (PDGFRalpha and PDGFRbeta), vascular endothelial growth factor (VEGF), VEGF-C, VEGF receptor 1, 2, and 3 (VEGFR1, VEGFR2, and VEGFR3), fibroblast growth factor (FGF), FMS-like tyrosine kinase 3 (FLT3), KIT (stem cell factor receptor), and RET (rearranged during transfection).","timeFrame":"Day 1 of Week 1 and every 4 weeks up to 1 year"},{"measure":"PFS in Subgroups Defined by RNA Expression Profiles of Tumors","description":"PFS defined as time in weeks from start of study treatment to first documentation of objective tumor progression or death due to any cause. PFS was to be determined in subgroups defined by RNA Gene expression (CSF-1R, PDGFRalpha, PDGFRbeta, VEGF, VEGF-C, VEGFR1, VEGFR2, VEGFR3, FGF, FLT3, KIT, and RET) level (low/high relative to expression of Glyceraldehyde-3-Phosphate Dehydrogenase \\[GAPDH\\] reference gene). PFS calculated as (first event date minus the date of first dose of study medication plus 1) divided by 7.02.","timeFrame":"Day 1 of Week 1 and every 4 weeks up to 1 year"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients with radiologically proven brain metastases secondary to non-small cell lung cancer\n* Received previous whole brain radiation therapy and none, 1 or 2 prior systemic therapy for the treatment of advanced/metastatic non-small cell lung cancer\n\nExclusion Criteria:\n\n* Patients with brainstem lesions, spinal cord compression. carcinomatous meningitis, or leptomeningeal disease.\n* Brain metastases \\>4 cm in any linear direction\n* Intracranial or intratumoral hemorrhage","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Pfizer CT.gov Call Center","affiliation":"Pfizer","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Pfizer Investigational Site","city":"Norwalk","state":"Connecticut","zip":"06856","country":"United States","geoPoint":{"lat":41.1176,"lon":-73.4079}},{"facility":"Pfizer Investigational Site","city":"Cocoa Beach","state":"Florida","zip":"32931","country":"United States","geoPoint":{"lat":28.32055,"lon":-80.60922}},{"facility":"Pfizer Investigational Site","city":"Merritt Island","state":"Florida","zip":"32952","country":"United States","geoPoint":{"lat":28.359,"lon":-80.69}},{"facility":"Pfizer Investigational Site","city":"Titusville","state":"Florida","zip":"32796","country":"United States","geoPoint":{"lat":28.61222,"lon":-80.80755}},{"facility":"Pfizer Investigational Site","city":"City of Saint Peters","state":"Missouri","zip":"63376","country":"United States","geoPoint":{"lat":38.80033,"lon":-90.62651}},{"facility":"Pfizer Investigational Site","city":"Creve Coeur","state":"Missouri","zip":"63141","country":"United States","geoPoint":{"lat":38.66089,"lon":-90.42262}},{"facility":"Pfizer Investigational Site","city":"St Louis","state":"Missouri","zip":"63110-1094","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Pfizer Investigational Site","city":"St Louis","state":"Missouri","zip":"63110","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Pfizer Investigational Site","city":"Basking Ridge","state":"New Jersey","zip":"07920","country":"United States","geoPoint":{"lat":40.70621,"lon":-74.54932}},{"facility":"Pfizer Investigational Site","city":"Commack","state":"New York","zip":"11725","country":"United States","geoPoint":{"lat":40.84288,"lon":-73.29289}},{"facility":"Pfizer Investigational Site","city":"New York","state":"New York","zip":"10022","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Pfizer Investigational Site","city":"Sayre","state":"Pennsylvania","zip":"18840","country":"United States","geoPoint":{"lat":41.97896,"lon":-76.5155}},{"facility":"Pfizer Investigational Site","city":"Austin","state":"Texas","zip":"78705","country":"United States","geoPoint":{"lat":30.26715,"lon":-97.74306}},{"facility":"Pfizer Investigational Site","city":"Austin","state":"Texas","zip":"78745","country":"United States","geoPoint":{"lat":30.26715,"lon":-97.74306}},{"facility":"Pfizer Investigational Site","city":"Austin","state":"Texas","zip":"78758","country":"United States","geoPoint":{"lat":30.26715,"lon":-97.74306}},{"facility":"Pfizer Investigational Site","city":"Austin","state":"Texas","zip":"78759","country":"United States","geoPoint":{"lat":30.26715,"lon":-97.74306}},{"facility":"Pfizer Investigational Site","city":"Round Rock","state":"Texas","zip":"78664","country":"United States","geoPoint":{"lat":30.50826,"lon":-97.6789}},{"facility":"Pfizer Investigational Site","city":"Pessac","state":"Be1 04495","zip":"33604","country":"France","geoPoint":{"lat":44.80565,"lon":-0.6324}},{"facility":"Pfizer Investigational Site","city":"Saint-Priest-en-Jarez","state":"France","zip":"42271","country":"France","geoPoint":{"lat":45.4739,"lon":4.37678}},{"facility":"Pfizer Investigational Site","city":"Marseille","zip":"13009","country":"France","geoPoint":{"lat":43.29695,"lon":5.38107}},{"facility":"Pfizer Investigational Site","city":"Toulouse","zip":"31059","country":"France","geoPoint":{"lat":43.60426,"lon":1.44367}},{"facility":"Pfizer Investigational Site","city":"Bologna","zip":"40139","country":"Italy","geoPoint":{"lat":44.49381,"lon":11.33875}},{"facility":"Pfizer Investigational Site","city":"Genova","zip":"16132","country":"Italy","geoPoint":{"lat":45.21604,"lon":11.87211}},{"facility":"Pfizer Investigational Site","city":"Orbassano (TO)","zip":"10043","country":"Italy","geoPoint":{"lat":45.00547,"lon":7.53813}},{"facility":"Pfizer Investigational Site","city":"Roma","zip":"00151","country":"Italy","geoPoint":{"lat":44.99364,"lon":11.10642}},{"facility":"Pfizer Investigational Site","city":"Madrid","state":"Madrid","zip":"28046","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Pfizer Investigational Site","city":"Valencia","state":"Valencia","zip":"46014","country":"Spain","geoPoint":{"lat":39.47391,"lon":-0.37966}}]},"referencesModule":{"seeAlsoLinks":[{"label":"To obtain contact information for a study center near you, click here.","url":"https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A6181092&StudyName=Study%20Tests%20The%20Safety%20And%20Effectiveness%20Of%20SU011248%20In%20Patients%20With%20Non-Small%20Cell%20Lung%20Cancer%20Having%20Brain%20Metastases"}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Sunitinib","description":"Sunitinib 37.5 mg oral capsule daily"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"66"}]},{"type":"Received Treatment","achievements":[{"groupId":"FG000","numSubjects":"64"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"3"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"63"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"8"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"15"}]},{"type":"Objective progression or relapse","reasons":[{"groupId":"FG000","numSubjects":"30"}]},{"type":"Global deterioration of health status","reasons":[{"groupId":"FG000","numSubjects":"6"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"1"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"1"}]},{"type":"Not Treated","reasons":[{"groupId":"FG000","numSubjects":"2"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Sunitinib","description":"Sunitinib 37.5 mg oral capsule daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"64"}]}],"measures":[{"title":"Age, Customized","paramType":"NUMBER","unitOfMeasure":"Participants","classes":[{"title":"Between 18 and 44 years","categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}]},{"title":"Between 45 and 64 years","categories":[{"measurements":[{"groupId":"BG000","value":"40"}]}]},{"title":">= 65 years","categories":[{"measurements":[{"groupId":"BG000","value":"20"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"25"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"39"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Progression-Free Survival (PFS)","description":"Time in weeks from start of study treatment to first documentation of objective tumor progression or death due to any cause. Since day of first dose of medication and day criteria for progression were met, were each counted as a full day, 1 day was added to each calculation. PFS calculated as (first event date minus date of first dose of study medication plus 1) divided by 7.02. Used 7.02 days because it equals(=) 365 days per year divided by 52 weeks per year. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \\[PD\\]).","populationDescription":"Intent-to-treat (ITT): all participants enrolled in the study who received at least 1 dose of study medication.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"90% Confidence Interval","unitOfMeasure":"Weeks","timeFrame":"Baseline, Day 1 of Week 5, 9, 17, 25, 33, and 41 to tumor progression or death (up to 1 year)","groups":[{"id":"OG000","title":"Sunitinib","description":"Sunitinib 37.5 mg oral capsule daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.4","lowerLimit":"7.5","upperLimit":"13.1"}]}]}]},{"type":"SECONDARY","title":"Time to Tumor Progression (TTP)","description":"Time from start of study treatment to first documentation of objective tumor progression. Tumor progression defined as greater than or equal to 20 percent (≥20%) increase in sum of longest dimensions of target lesions using as reference smallest sum of longest dimensions recorded since treatment started, or unequivocal progression of existing non-target lesions, or appearance of ≥1 new lesion, according to Response Evaluation Criteria in Solid Tumors (RECIST). TTP = (first event date minus date of first dose of study medication plus 1) divided by 7.02.","populationDescription":"ITT","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Weeks","timeFrame":"Baseline, Day 1 of Week 5, 9, 17, 25, 33, and 41 to tumor progression (up to 1 year)","groups":[{"id":"OG000","title":"Sunitinib","description":"Sunitinib 37.5 mg oral capsule daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.1","lowerLimit":"8.4","upperLimit":"15.8"}]}]}]},{"type":"SECONDARY","title":"Time to Neurological Progression (TNP)","description":"Time in weeks between first date criteria for focal neurological deficit were met and date of first dose of medication. Criteria for focal neurological deficit included speech or language difficulties, vision changes, loss of coordination or fine motor control, and seizures. Since day of first dose of medication and day criteria for focal neurological deficit were met were each counted as a full day, 1 day was added to each calculation. TNP was calculated as (first event date minus the date of first dose of study medication plus 1) divided by 7.02.","populationDescription":"ITT","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"Weeks","timeFrame":"Baseline, Day 28 to focal neurological deficit (up to 1 year)","groups":[{"id":"OG000","title":"Sunitinib","description":"Sunitinib 37.5 mg oral capsule daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","lowerLimit":"0.4","upperLimit":"58.8"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Objective Disease Response","description":"Objective disease response defined as participants with confirmed complete response (CR) or partial response (PR), according to Response Evaluation Criteria in Solid Tumors (RECIST). CR defined as disappearance of all target lesions. PR defined as ≥30% decrease in sum of longest dimensions of target lesions taking as a reference the baseline sum longest dimensions.","populationDescription":"ITT with measurable disease at baseline.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Baseline and Day 1 of Week 5, 9, 17, 25, 33, 41, and 49","groups":[{"id":"OG000","title":"Sunitinib","description":"Sunitinib 37.5 mg oral capsule daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"61"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}],"analyses":[{"groupIds":["OG000"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Objective Response Rate (ORR) (percent)","paramValue":"1.6","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.0","ciUpperLimit":"8.8","estimateComment":"Two-Sided Confidence Interval (CI) from Exact Method using the F Distribution"}]},{"type":"SECONDARY","title":"Time to Objective Intracranial Progression","description":"Time in weeks from start of study treatment to first documentation of objective intracranial tumor progression. Intracranial tumor progression defined as ≥25% increase from smallest size in sum of products of all enhancing tumors or appearance of any new tumor, according to World Health Organization (WHO) criteria. Since day of first dose of medication and day criteria for progression were met, were each counted as a full day, 1 day added to each calculation. Time to Objective Intracranial Progression = (first event date minus the date of first dose of study medication plus 1) divided by 7.02.","populationDescription":"ITT","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Weeks","timeFrame":"Baseline, Day 1 of Week 5, 9, 17, 25, 33, and 41 to intracranial tumor progression (up to 1 year)","groups":[{"id":"OG000","title":"Sunitinib","description":"Sunitinib 37.5 mg oral capsule daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.4","lowerLimit":"12.1","upperLimit":"24.8"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Intracranial Objective Disease Response","description":"Intracranial objective disease response defined as participants with confirmed CR or PR, according to WHO criteria. CR defined as disappearance of all enhancing tumor. PR defined as a ≥50% reduction from baseline in sum of the products of all enhancing tumors.","populationDescription":"ITT with measurable intracranial disease at baseline.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Baseline and Day 1 of Week 5, 9, 17, 25, 33, 41, and 49","groups":[{"id":"OG000","title":"Sunitinib","description":"Sunitinib 37.5 mg oral capsule daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}],"analyses":[{"groupIds":["OG000"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"ORR (percent)","paramValue":"4.3","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.1","ciUpperLimit":"21.9","estimateComment":"Two-Sided CI from Exact Method using the F Distribution"}]},{"type":"SECONDARY","title":"Duration of Response (DR)","description":"DR defined as difference in weeks between first date criteria for progression occurred, or participant died due to any cause and first date that criteria for a PR or CR were met and subsequently confirmed ≥4 weeks later. Since day criteria for PR or CR were met and first day criteria for progression occurred (or participant died) were each counted as a full day, 1 day was added to each calculation. DR (in weeks) calculated as (first date of PD or death minus first date of CR or PR that was subsequently confirmed plus 1) divided by 7.02.","populationDescription":"ITT. DR only calculated for the subgroup of participants with an objective tumor response.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Weeks","timeFrame":"Day 7 of Week 4 and every 4 weeks up to 1 year","groups":[{"id":"OG000","title":"Sunitinib","description":"Sunitinib 37.5 mg oral capsule daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"classes":[{"title":"Overall","categories":[{"measurements":[{"groupId":"OG000","value":"32.1"}]}]},{"title":"Intracranial","categories":[{"measurements":[{"groupId":"OG000","value":"8.26"}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"OS calculated as: (date of death minus date of first dose plus 1)divided by 30.4.","populationDescription":"ITT. In the absence of confirmation of death, survival time was censored to last date of known contact.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Baseline until death (up to 1 year)","groups":[{"id":"OG000","title":"Sunitinib","description":"Sunitinib 37.5 mg oral capsule daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.8","lowerLimit":"3.1","upperLimit":"8.2"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Surviving at 1 Year","description":"Percentage of those surviving at end of 1 year from the first dose of study treatment.","populationDescription":"ITT","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Year 1","groups":[{"id":"OG000","title":"Sunitinib","description":"Sunitinib 37.5 mg oral capsule daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.4","lowerLimit":"14.0","upperLimit":"34.3"}]}]}],"analyses":[{"groupIds":["OG000"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Percentage","paramValue":"23.4","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"14.0","ciUpperLimit":"34.3","estimateComment":"Probability of survival along with the corresponding 2-sided confidence interval for the log \\[-log(one-year survival rate)\\] calculated using a normal approximation and then back transformed to give a confidence interval for the one-year survival"}]},{"type":"SECONDARY","title":"Number of Deaths Due to Intracranial Versus Systemic Progression","description":"Number of deaths determined to be intracranial versus systemic progression, according to investigators'assessment.","populationDescription":"ITT","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Baseline until death (up to 1 year)","groups":[{"id":"OG000","title":"Sunitinib","description":"Sunitinib 37.5 mg oral capsule daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"}]}],"classes":[{"title":"Systemic Progression","categories":[{"measurements":[{"groupId":"OG000","value":"48"}]}]},{"title":"Intracranial Progression","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Functional Assessment of Cancer Therapy/National Comprehensive Cancer Network (FACT/NCCN) Lung Symptom Index (FLSI) Score","description":"Change from baseline in FLSI Score was calculated Day 1 of Cycle 2 to 13. Each cycle = 28 days. Scores ranged from 0 to 24. Higher scores indicated better outcomes.","populationDescription":"ITT population of participants with post baseline patient-reported outcome data","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Scores on a scale","timeFrame":"Baseline, Day 1 of Week 5 and every 4 weeks to end of treatment (up to 1 year)","groups":[{"id":"OG000","title":"Sunitinib","description":"Sunitinib 37.5 mg oral capsule daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"45"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"17.62","lowerLimit":"16.01","upperLimit":"19.22"}]}]},{"title":"Cycle 2, Day 1","categories":[{"measurements":[{"groupId":"OG000","value":"0.52","lowerLimit":"-0.89","upperLimit":"1.92"}]}]},{"title":"Cycle 3, Day 1","categories":[{"measurements":[{"groupId":"OG000","value":"1.11","lowerLimit":"-0.57","upperLimit":"2.80"}]}]},{"title":"Cycle 4, Day 1","categories":[{"measurements":[{"groupId":"OG000","value":"-0.48","lowerLimit":"-2.94","upperLimit":"1.99"}]}]},{"title":"Cycle 5, Day 1","categories":[{"measurements":[{"groupId":"OG000","value":"0.64","lowerLimit":"-1.03","upperLimit":"2.31"}]}]},{"title":"Cycle 6, Day 1","categories":[{"measurements":[{"groupId":"OG000","value":"-0.63","lowerLimit":"-2.30","upperLimit":"1.05"}]}]},{"title":"Cycle 7, Day 1","categories":[{"measurements":[{"groupId":"OG000","value":"-0.66","lowerLimit":"-2.14","upperLimit":"0.82"}]}]},{"title":"Cycle 8, Day 1","categories":[{"measurements":[{"groupId":"OG000","value":"-0.66","lowerLimit":"-1.76","upperLimit":"0.45"}]}]},{"title":"Cycle 9, Day 1","categories":[{"measurements":[{"groupId":"OG000","value":"-0.60","lowerLimit":"-2.55","upperLimit":"1.35"}]}]},{"title":"Cycle10, Day 1","categories":[{"measurements":[{"groupId":"OG000","value":"-0.12","lowerLimit":"-2.47","upperLimit":"2.23"}]}]},{"title":"Cycle 11, Day 1","categories":[{"measurements":[{"groupId":"OG000","value":"-0.20","lowerLimit":"-2.96","upperLimit":"2.56"}]}]},{"title":"Cycle 12, Day 1","categories":[{"measurements":[{"groupId":"OG000","value":"-0.40","lowerLimit":"-2.99","upperLimit":"2.19"}]}]},{"title":"Cycle 13, Day 1","categories":[{"measurements":[{"groupId":"OG000","value":"-0.80","lowerLimit":"-10.96","upperLimit":"9.36"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in FACT/NCCN Brain Symptom Index (FBrSI) Score","description":"Change from baseline in FBrSI Score was calculated Day 1 of Cycle 2 to 13. Each cycle = 28 days. Scores ranged from 0 to 60. Higher scores indicated better outcomes.","populationDescription":"ITT population of participants with post baseline patient-reported outcome data","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Scores on a scale","timeFrame":"Baseline, Day 1 of Week 5 and every 4 weeks to end of treatment (up to 1 year)","groups":[{"id":"OG000","title":"Sunitinib","description":"Sunitinib 37.5 mg oral capsule daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"45"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"45.72","lowerLimit":"43.52","upperLimit":"47.92"}]}]},{"title":"Cycle 2, Day 1","categories":[{"measurements":[{"groupId":"OG000","value":"-1.25","lowerLimit":"-2.84","upperLimit":"0.34"}]}]},{"title":"Cycle 3, Day 1","categories":[{"measurements":[{"groupId":"OG000","value":"-0.58","lowerLimit":"-3.52","upperLimit":"2.37"}]}]},{"title":"Cycle 4, Day 1","categories":[{"measurements":[{"groupId":"OG000","value":"0.66","lowerLimit":"-2.34","upperLimit":"3.65"}]}]},{"title":"Cycle 5, Day 1","categories":[{"measurements":[{"groupId":"OG000","value":"-1.87","lowerLimit":"-5.21","upperLimit":"1.46"}]}]},{"title":"Cycle 6, Day 1","categories":[{"measurements":[{"groupId":"OG000","value":"-1.92","lowerLimit":"-5.96","upperLimit":"2.12"}]}]},{"title":"Cycle 7, Day 1","categories":[{"measurements":[{"groupId":"OG000","value":"-2.00","lowerLimit":"-5.80","upperLimit":"1.80"}]}]},{"title":"Cycle 8, Day 1","categories":[{"measurements":[{"groupId":"OG000","value":"-0.73","lowerLimit":"-4.46","upperLimit":"2.99"}]}]},{"title":"Cycle 9, Day 1","categories":[{"measurements":[{"groupId":"OG000","value":"0.40","lowerLimit":"-3.07","upperLimit":"3.88"}]}]},{"title":"Cycle 10, Day 1","categories":[{"measurements":[{"groupId":"OG000","value":"-1.83","lowerLimit":"-5.11","upperLimit":"1.45"}]}]},{"title":"Cycle 11, Day 1","categories":[{"measurements":[{"groupId":"OG000","value":"-1.50","lowerLimit":"-6.09","upperLimit":"3.09"}]}]},{"title":"Cycle 12, Day 1","categories":[{"measurements":[{"groupId":"OG000","value":"-4.50","lowerLimit":"-15.33","upperLimit":"6.33"}]}]},{"title":"Cycle 13, Day 1","categories":[{"measurements":[{"groupId":"OG000","value":"1.21","lowerLimit":"-8.77","upperLimit":"11.20"}]}]}]},{"type":"SECONDARY","title":"Trough Plasma Concentrations (Ctrough) of Sunitinib","description":"A single blood sample (4 milliliters \\[mL\\]) collected pre-dose on Day 1 of Cycles 2, 3, and 4 to determine Ctrough of Sunitinib and its metabolite SU12662. Each cycle = 28 days. Ctrough defined as plasma concentration prior to study drug administration. Trough plasma concentrations were dose-corrected.","populationDescription":"ITT participants who had pharmacokinetic results for at least 1 day. Ctrough only calculated for subgroup of participants with observations (non-missing concentrations). n = number of participants with evaluable data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"nanograms per milliliter (ng/mL)","timeFrame":"Day 1 of Week 5, 9, and 13","groups":[{"id":"OG000","title":"Sunitinib","description":"Sunitinib 37.5 mg oral capsule daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"}]}],"classes":[{"title":"Cycle 2, Day 1 (n = 26)","categories":[{"measurements":[{"groupId":"OG000","value":"50.89","spread":"20.47"}]}]},{"title":"Cycle 3, Day 1 (n = 21)","categories":[{"measurements":[{"groupId":"OG000","value":"46.27","spread":"17.97"}]}]},{"title":"Cycle 4, Day 1 (n = 20)","categories":[{"measurements":[{"groupId":"OG000","value":"51.10","spread":"23.13"}]}]}]},{"type":"SECONDARY","title":"Ctrough of Sunitinib Metabolite (SU012662)","description":"A single blood sample (4 mL) collected pre-dose on Day 1 of Cycles 2, 3, and 4 to determine Ctrough of Sunitinib and its metabolite SU12662. Each cycle = 28 days. Ctrough defined as plasma concentration prior to study drug administration. Trough plasma concentrations were dose-corrected.","populationDescription":"ITT participants who had pharmacokinetic results for at least 1 day. Ctrough only calculated for subgroup of participants with observations (non-missing concentrations). n = number of participants with evaluable data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ng/mL","timeFrame":"Day 1 of Week 5, 9, and 13","groups":[{"id":"OG000","title":"Sunitinib","description":"Sunitinib 37.5 mg oral capsule daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"}]}],"classes":[{"title":"Cycle 2, Day 1 (n = 26)","categories":[{"measurements":[{"groupId":"OG000","value":"33.85","spread":"17.64"}]}]},{"title":"Cycle 3, Day 1 (n = 21)","categories":[{"measurements":[{"groupId":"OG000","value":"28.45","spread":"15.73"}]}]},{"title":"Cycle 4, Day 1 ( n = 20)","categories":[{"measurements":[{"groupId":"OG000","value":"28.91","spread":"18.82"}]}]}]},{"type":"SECONDARY","title":"Correlation of Polymorphisms in c-Kit, Flt-3 and c-Fms With Blood Counts","description":"A blood sample (6mL) collected before treatment with Sunitinib and used to isolate deoxyribonucleic acid (DNA). These samples were not anonymized.","populationDescription":"ITT. c-Kit, Flt-3 and c-Fms with blood count samples collected; however, no statistical analyses performed since power was insufficient.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"picograms per milliliter (pg/mL)","timeFrame":"Day 1 prior to dosing","groups":[{"id":"OG000","title":"Sunitinib","description":"Sunitinib 37.5 mg oral capsule daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"}]}]},{"type":"SECONDARY","title":"Percentage of Participants by Ribonucleic Acid (RNA) Expression Profile","description":"Tumor samples were not anonymized. RNA expression profile was to include colony-stimulating factor 1 receptor (CSF-1R), platelet-derived growth factor receptor alpha and beta (PDGFRalpha and PDGFRbeta), vascular endothelial growth factor (VEGF), VEGF-C, VEGF receptor 1, 2, and 3 (VEGFR1, VEGFR2, and VEGFR3), fibroblast growth factor (FGF), FMS-like tyrosine kinase 3 (FLT3), KIT (stem cell factor receptor), and RET (rearranged during transfection).","populationDescription":"ITT. Only 4 RNA samples were collected and no statistical analyses performed.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Day 1 of Week 1 and every 4 weeks up to 1 year","groups":[{"id":"OG000","title":"Sunitinib","description":"Sunitinib 37.5 mg oral capsule daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"}]}]},{"type":"SECONDARY","title":"PFS in Subgroups Defined by RNA Expression Profiles of Tumors","description":"PFS defined as time in weeks from start of study treatment to first documentation of objective tumor progression or death due to any cause. PFS was to be determined in subgroups defined by RNA Gene expression (CSF-1R, PDGFRalpha, PDGFRbeta, VEGF, VEGF-C, VEGFR1, VEGFR2, VEGFR3, FGF, FLT3, KIT, and RET) level (low/high relative to expression of Glyceraldehyde-3-Phosphate Dehydrogenase \\[GAPDH\\] reference gene). PFS calculated as (first event date minus the date of first dose of study medication plus 1) divided by 7.02.","populationDescription":"ITT. Only 4 RNA samples were collected and no statistical analyses performed.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"90% Confidence Interval","unitOfMeasure":"weeks","timeFrame":"Day 1 of Week 1 and every 4 weeks up to 1 year","groups":[{"id":"OG000","title":"Sunitinib","description":"Sunitinib 37.5 mg oral capsule daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","description":"The same event may appear as both an adverse event (AE) and a serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 subject and as nonserious in another subject, or 1 subject may have experienced both a serious and nonserious event during the study.","eventGroups":[{"id":"EG000","title":"Sunitinib","description":"Sunitinib 37.5 mg oral capsule daily","seriousNumAffected":34,"seriousNumAtRisk":64,"otherNumAffected":63,"otherNumAtRisk":64}],"seriousEvents":[{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":64}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":64}]},{"term":"Cardiac tamponade","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":64}]},{"term":"Pericarditis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":64}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":64}]},{"term":"Aphthous stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":64}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":64}]},{"term":"Duodenal ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":64}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":64}]},{"term":"Glossodynia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":64}]},{"term":"Oral pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":64}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":64}]},{"term":"Disease progression","organSystem":"General disorders","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":64}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":64}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":64}]},{"term":"Jaundice","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":64}]},{"term":"Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":64}]},{"term":"Lung infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":64}]},{"term":"Pyelonephritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":64}]},{"term":"Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":64}]},{"term":"Pulmonary function test decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":64}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":64}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":64}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":64}]},{"term":"Cerebellar syndrome","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":64}]},{"term":"Cerebral ischaemia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":64}]},{"term":"Convulsion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":64}]},{"term":"Epilepsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":64}]},{"term":"Tremor","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":64}]},{"term":"Intentional self-injury","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":64}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":64}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":64}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":64}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":64}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":64}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":64}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":64}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":64}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":64}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":64}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":64}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":64}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":64}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":64}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":64}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":64}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":64}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":64}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":23,"numAtRisk":64}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":64}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":64}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":64}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":64}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":64}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":64}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":64}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":64}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":64}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":64}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":64}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":64}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":64}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":64}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results."},"pointOfContact":{"title":"Pfizer ClinicalTrials.gov Call Center","organization":"Pfizer, Inc.","email":"ClinicalTrials.gov_Inquiries@pfizer.com","phone":"1-800-718-1021"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"},{"id":"D001932","term":"Brain Neoplasms"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"},{"id":"D016543","term":"Central Nervous System Neoplasms"},{"id":"D009423","term":"Nervous System Neoplasms"},{"id":"D001927","term":"Brain Diseases"},{"id":"D002493","term":"Central Nervous System Diseases"},{"id":"D009422","term":"Nervous System Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000077210","term":"Sunitinib"}],"ancestors":[{"id":"D011758","term":"Pyrroles"},{"id":"D001393","term":"Azoles"},{"id":"D006573","term":"Heterocyclic Compounds, 1-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D007211","term":"Indoles"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"}]}},"hasResults":true}